Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia

Michael Steurer, Marco Montillo, Lydia Scarfò, Francesca R. Mauro, Johannes Andel, Sophie Wildner, Livio Trentin, Ann Janssens, Sonja Burgstaller, Anna Frömming, Thomas Dümmler, Kai Riecke, Matthias Baumann, Diana Beyer, Stéphanie Vauléon, Paolo Ghia, Robin Foà, Federico Caligaris-Cappio, and Marco Gobbi

Disclosures: MM: honoraria, advisory board and/or speaker bureau for AbbVie, Janssen, Gilead and Roche. FRM: advisory board and/or speaker bureau for Janssen, Gilead, Roche, AbbVie. RF: advisory board and/or speaker bureau for Janssen, Celgene, Gilead, Roche, Amgen, AbbVie, Sandoz, Novartis, Incyte. PG: Honoraria: AbbVie, Gilead, Janssen, Roche; Research funding: AbbVie, Gilead, Janssen, Novartis. LS received honoraria from Janssen, Gilead, Roche and AbbVie. AF, SV, TD, KR, MB and DB are/were employees of NOXXON Pharma incl. stock ownership.

Contributions: MS, MM, LS, FRM, JA, SW, LT, AJ, SB, PG, RF, FCC and MG performed clinical research. MS, AF, SV, TD, DB, MB and KR performed analysis and interpretation of data. MS and AF wrote the initial draft of the manuscript and edited the final draft. All authors reviewed the manuscript and approved the final version for submission.